Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)
Progression‐free survival · People with squamous cell carcinoma of the oral cavity or oropharynx
It is very uncertain whether tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… changes progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (very low certainty).
1 finding from 1 review
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes40 to 60 monthsHR 0.80 [0.51, 1.28]2 studies · 271 participantsVery low